Bazı göz hastalıklarının tedavisinde kullanılan ranibizumab‘ın biyobenzerini geliştiren G.Kore merkezli Samsung Bioepis , 24 haftalık Faz3 çalışmasında referans ürünle benzer sonuçların alındığını açıkladı.
Samsung Bioepis Reports Equivalency for Ranibizumab Biosimilar
After completing a 24-week phase 3 trial, Samsung Bioepis said its biosimilar ranibizumab (SB11) has demonstrated clinical equivalence to reference Lucentis for the treatment of neovascular age-related macular degeneration.
outh Korea-based Samsung Bioepis announced that its ranibizumab biosimilar (SB11) demonstrated equivalent efficacy, safety, and immunogenicity to the reference product (Lucentis) in a 24-week phase 3 clinical trial involving patients with neovascular age-related macular degeneration (nAMD).
